Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease

AIMS: Finerenone, a selective, non-steroidal mineralocorticoid receptor antagonist, improves cardiovascular (CV) and kidney outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). This subgroup analysis of FIDELITY, a pre-specified, pooled, individual patient-data analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Filippatos, Gerasimos, Anker, Stefan D, Pitt, Bertram, McGuire, Darren K, Rossing, Peter, Ruilope, Luis M, Butler, Javed, Jankowska, Ewa A, Michos, Erin D, Farmakis, Dimitrios, Farjat, Alfredo E, Kolkhof, Peter, Scalise, Andrea, Joseph, Amer, Bakris, George L, Agarwal, Rajiv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753093/
https://www.ncbi.nlm.nih.gov/pubmed/36251465
http://dx.doi.org/10.1093/ehjcvp/pvac054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753093/
https://www.ncbi.nlm.nih.gov/pubmed/36251465
http://dx.doi.org/10.1093/ehjcvp/pvac054

Ejemplares similares